Core Viewpoint - BriaCell Therapeutics Corp. has completed a transaction where its subsidiary, BriaPro Therapeutics Corp., acquired the exclusive license to develop and commercialize Soluble CD80 (sCD80) for cancer treatment, which is expected to enhance cancer care through novel immunotherapy approaches [1][3][10]. Group 1: Transaction Details - BriaPro acquired worldwide rights to develop and commercialize sCD80, while the University of Maryland retains certain rights, with BriaPro obligated to pay 2% royalties upon commercialization [3]. - BriaCell has provided BriaPro with up to $3 million in a Credit Facility to support research and development, subject to BriaCell's approval [4]. - As part of the transaction, BriaPro issued 23,972,589 Common Shares to BriaCell, valued at approximately C$1.18 million, increasing BriaCell's ownership in BriaPro to about 78% [5][11]. Group 2: Leadership and Governance - Jamieson Bondarenko was appointed as Chairman of BriaPro's board following the transaction, bringing extensive experience in investment banking and corporate development [6]. - The transaction received overwhelming approval from 99.81% of disinterested shareholders of BriaPro, ensuring compliance with minority security holder protection regulations [7]. Group 3: Research and Development Potential - The technology behind sCD80, developed by Dr. Suzanne Ostrand-Rosenberg, has shown promise in animal models by halting tumor growth and potentially restoring anti-tumor immunity [2]. - BriaCell aims to explore the use of sCD80 in combination with other immunotherapies, highlighting its potential as a transformative treatment for cancer patients [10].

Core Viewpoint - BriaCell Therapeutics Corp. and its subsidiary BriaPro Therapeutics Corp. have entered into a definitive purchase agreement for BriaPro to acquire BriaCell's exclusive license for the development and commercialization of Soluble CD80 (sCD80) as a biologic agent for cancer treatment [1][3]. Background - BriaCell secured the exclusive license for sCD80 from the University of Maryland, Baltimore County (UMBC) on August 2, 2022, which is based on technology developed by Dr. Suzanne Ostrand-Rosenberg [2]. - sCD80 has shown promise in animal models by halting tumor growth and potentially restoring anti-tumor immunity, with reported strong anti-tumor activity across multiple tumor types [2]. Transaction Details - BriaPro will gain worldwide rights to develop and commercialize sCD80, while UMBC retains certain rights, including a 2% royalty on commercialization and other development costs [3]. - BriaCell will provide up to $3 million to BriaPro for research and development, with fund usage subject to BriaCell's approval [4]. - As part of the transaction, BriaPro will issue 23,972,589 Common Shares to BriaCell, valued at approximately C$1.18 million, increasing BriaCell's ownership in BriaPro to about 78% post-transaction [5]. Shareholder Approval - The Purchase Agreement requires approval from a simple majority of disinterested shareholders of BriaPro, excluding votes from BriaCell due to its 10% stake [6]. - BriaPro plans to comply with formal valuation requirements under Multilateral Instrument 61-101, intending to obtain an independent third-party valuation to confirm fair market value [7][8]. Company Statements - The President and CEO of BriaCell and BriaPro emphasized the mission to develop effective cancer treatments, highlighting the potential of sCD80 as a transformational anti-cancer agent [9].

Core Viewpoint - BriaCell Therapeutics Corp. and its subsidiary BriaPro Therapeutics Corp. have entered into a definitive purchase agreement for BriaPro to acquire BriaCell's exclusive license for the development and commercialization of Soluble CD80 (sCD80) as a biologic agent for cancer treatment, which is expected to enhance cancer care through novel immunotherapies [1][3][9] Group 1: Transaction Details - BriaPro will gain worldwide rights to develop and commercialize sCD80, while the University of Maryland, Baltimore County (UMBC) retains rights to the inventions and patents, with BriaPro obligated to pay 2% royalties upon commercialization [3] - BriaCell will provide up to $3 million to BriaPro for research and development, with fund usage subject to BriaCell's approval [4] - As part of the transaction, BriaPro will issue 23,972,589 Common Shares to BriaCell, valued at approximately C$1.18 million, increasing BriaCell's ownership in BriaPro to about 78% post-transaction [5] Group 2: Approval and Valuation - The transaction requires approval from a simple majority of BriaPro's shareholders, excluding votes from BriaCell due to its 10% stake [6] - BriaPro plans to obtain a third-party valuation to ensure the transaction occurs at fair market value, despite a formal valuation not being legally required [8] Group 3: Background on sCD80 - The technology for sCD80 was developed by Dr. Suzanne Ostrand-Rosenberg and has shown promise in animal models by halting tumor growth and potentially restoring anti-tumor immunity [2] - Studies indicate that sCD80 may enhance the immune system's ability to recognize and destroy tumor cells, demonstrating strong anti-tumor activity across multiple tumor types [2]